CancerDrs

Pancreatic Cancer clinical trials in Maryland

46 actively recruiting pancreatic cancer trials at 14 sites across Maryland.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care …

Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Maryland:
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • William E Kahlert Regional Cancer Center/Sinai Hospital — Westminster, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Maryland:
  • Sinai Hospital of Baltimore — Baltimore, Maryland
  • Christiana Care - Union Hospital — Elkton, Maryland
  • Northwest Hospital Center — Randallstown, Maryland
  • William E Kahlert Regional Cancer Center/Sinai Hospital — Westminster, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Sites in Maryland:
  • Christiana Care - Union Hospital — Elkton, Maryland
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…

Sponsor: Pfizer
NCT ID: NCT06989437
Sites in Maryland:
  • JHU Oncology Central Kit Services — Baltimore, Maryland
  • Johns Hopkins Hospital — Baltimore, Maryland
  • Oncology Investigational Drug Service (IDS) — Baltimore, Maryland
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Maryland:
  • University of Maryland School of Medicine (Adults only) — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07491445
Sites in Maryland:
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

The Cancer of the Pancreas Screening-5 CAPS5)Study

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in Maryland:
  • Johns Hopkins Hospital — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Maryland:
  • Maryland Oncology Hematology - Primary — Columbia, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Maryland:
  • The Sidney Kimmel Comprehensive Cancer Center at John Hopkins — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BM…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07492680
Sites in Maryland:
  • Johns Hopkins Hospital — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04924075
Sites in Maryland:
  • Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108) — Baltimore, Maryland
  • National Institutes of Health ( Site 0125) — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07223047
Sites in Maryland:
  • Johns Hopkins Hospital — Baltimore, Maryland
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These ce…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01174121
Sites in Maryland:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cell…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03190941
Sites in Maryland:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is call…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT02830724
Sites in Maryland:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
View on ClinicalTrials.gov →

Showing 25 of 46 trials with sites in Maryland. See all pancreatic cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12